Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2020 2
2021 6
2022 6
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: schlam i. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Best of the year: Advanced breast cancer in 2023.
Schlam I, Chavez-MacGregor M. Schlam I, et al. Breast. 2024 Apr;74:103677. doi: 10.1016/j.breast.2024.103677. Epub 2024 Feb 14. Breast. 2024. PMID: 38401422 Free PMC article. Review.
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.
Cobanaj M, Corti C, Dee EC, McCullum L, Boldrini L, Schlam I, Tolaney SM, Celi LA, Curigliano G, Criscitiello C. Cobanaj M, et al. Among authors: schlam i. Eur J Cancer. 2024 Feb;198:113504. doi: 10.1016/j.ejca.2023.113504. Epub 2023 Dec 19. Eur J Cancer. 2024. PMID: 38141549 Free article. Review.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: schlam i. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. PMID: 38105958 Free PMC article. Updated. Preprint.
Managing adverse events of sacituzumab govitecan.
Schlam I, Tarantino P, Tolaney SM. Schlam I, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1103-1111. doi: 10.1080/14712598.2023.2267975. Epub 2023 Dec 15. Expert Opin Biol Ther. 2023. PMID: 37800595 Review.
30 results